Want to see SE:ALZ full AI Analyst Report?
Top Page
Alzinova AB
(ALZ)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr0.94
▲(14.15% Upside)
Action:Reiterated
Date:08/22/26
The score is held back primarily by weak financial performance—ongoing operating losses and negative free cash flow indicating continued funding needs—partly offset by a strong, low-debt balance sheet. Technicals are mixed with soft short-term price action and subdued momentum, and valuation is constrained by negative earnings and no dividend support.
Positive Factors
Minimal debt and leverage
Minimal debt and very low leverage reduce financial risk while preserving flexibility to fund research, absorb setbacks, and pursue development priorities. This balance-sheet strength is particularly valuable for a clinical-stage biotechnology company whose future cash generation remains dependent on advancing candidates.
Negative Factors
Persistent cash burn
Negative operating and free cash flow show that Alzinova cannot currently fund its activities from internal cash generation. Continued burn increases reliance on external financing or partnering proceeds, while deteriorating free cash flow could constrain the pace and scope of future development investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal debt and leverage
Minimal debt and very low leverage reduce financial risk while preserving flexibility to fund research, absorb setbacks, and pursue development priorities. This balance-sheet strength is particularly valuable for a clinical-stage biotechnology company whose future cash generation remains dependent on advancing candidates.
Read all positive factors
Alzinova AB (ALZ) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr182.17M
Dividend YieldN/A
Average Volume (3M)2.50M
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth-100.00%
EPS Growth20.96%
CountrySE
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.21
Shares Outstanding202,640,560
10 Day Avg. Volume1,113,728
30 Day Avg. Volume2,495,108
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.27
Revenue Forecast (FY)N/A
Alzinova AB Business Overview & Revenue Model
Company Description
Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for ...
How the Company Makes Money
Alzinova AB’s primary economic model is typical of early-stage biotechnology companies focused on drug development: it seeks to create shareholder value and potential future revenues by advancing proprietary drug candidates through preclinical and...
Alzinova AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.98M | 0.00 | 30.00K | 270.00K | 16.63M | 17.32M |
| Gross Profit | 15.05M | 26.55M | 16.81M | 19.87M | 33.27M | 34.64M |
| EBITDA | -25.63M | -25.85M | -20.32M | 42.00K | -13.07M | -7.52M |
| Net Income | -24.29M | -26.27M | -20.55M | -16.48M | -13.07M | -7.58M |
Balance Sheet | ||||||
| Total Assets | 163.57M | 143.43M | 133.23M | 123.19M | 111.62M | 91.69M |
| Cash, Cash Equivalents and Short-Term Investments | 13.31M | 319.00K | 15.50M | 22.03M | 32.04M | 28.84M |
| Total Debt | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K |
| Total Liabilities | 7.60M | 21.47M | 9.40M | 9.33M | 6.09M | 3.22M |
| Stockholders Equity | 155.97M | 121.96M | 123.82M | 113.86M | 105.53M | 88.47M |
Cash Flow | ||||||
| Free Cash Flow | -34.60M | -39.58M | -37.05M | -34.82M | -26.95M | -27.14M |
| Operating Cash Flow | -23.75M | -13.03M | -20.27M | -15.21M | -10.31M | -9.82M |
| Investing Cash Flow | -19.92M | -26.55M | -16.78M | -19.60M | -16.63M | -17.32M |
| Financing Cash Flow | 45.47M | 24.41M | 30.52M | 24.80M | 30.15M | 0.00 |
Alzinova AB Technical Analysis
Positive
0.82
Price Trends
0.87
Positive
0.67
Positive
0.79
Positive
Market Momentum
>-0.01
Negative
58.48
Neutral
69.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZ, the sentiment is Positive. The current price of 0.82 is below the 20-day moving average (MA) of 0.87, below the 50-day MA of 0.87, and above the 200-day MA of 0.79, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 58.48 is Neutral, neither overbought nor oversold. The STOCH value of 69.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ALZ.
Alzinova AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr29.16B | 278.32 | 5.18% | 0.65% | -46.09% | -90.13% | |
64 Neutral | kr1.53B | 8.14 | 29.71% | ― | 24.98% | -31.44% | |
52 Neutral | kr256.68M | -2.74 | -97.06% | ― | 4.74% | 66.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.16B | 56.53 | 65.99% | ― | ― | ― | |
45 Neutral | kr182.17M | -4.54 | -17.52% | ― | -100.00% | 20.96% | |
43 Neutral | kr130.62M | -12.27 | -93.01% | ― | ― | 54.60% |
* Healthcare Sector Average
SE:ALZ
Alzinova AB
0.96
-0.32
-25.00%
SE:ALZCUR
AlzeCure Pharma AB
8.44
5.64
201.21%
SE:BIOA.B
BioArctic AB Class B
331.20
47.88
16.90%
SE:SANION
Saniona AB
10.91
-1.39
-11.30%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.78
-0.88
-33.03%
SE:ACTI
Active Biotech AB
4.84
-7.88
-61.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.